XII. Referenzen


Mease PJ, Smolen JS, Behrens F et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic


98. Armstrong A, Paul C, Puig L et al. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. *Dermatology and therapy* 2019.


102. Visvanathan S, Baum P, Salas A et al. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study. *J. Crohns Colitis* 2018; 12: 1170-9.


Scott Fl, Mantani R, Brensinger CM *et al.* Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. *JAMA Dermatol* 2016; 152: 164-72.


179. Ford AR, Siegel M, Bagel J et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA Dermatol 2018; 154: 934-50.


194


307. Tang KT, Chen YM, Chang SN, Lin CH, Chen DY. Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term


334. European Medicines Agency. Acitretin 25mg Capsules - Summary of Product Characteristics (SmPC) - (emc). In.

335. European Medicines Agency. Otezla 30 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). In.


339. European Medicines Agency. Skilarence 30 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC) - (emc). In.


342. European Medicines Agency. Methotrexate 2.5mg Tablets - Summary of Product Characteristics (SmPC) - (emc). In.


